TY  - JOUR
AU  - Martínez, Carmen
AU  - Carpio, Cecilia
AU  - Heras, Inmaculada
AU  - Ríos-Herranz, Eduardo
AU  - Buch, Joan
AU  - Gutierrez, Antonio
AU  - Romero, Samuel
AU  - Zeberio, Izaskun
AU  - García-García, Irene
AU  - Rodriguez-Izquierdo, Antonia
AU  - Alonso, Rosalía
AU  - Bargay, Joan
AU  - Barrenetxea, Cristina
AU  - Domingo-Doménech, Eva
AU  - de Haro, Manuel Espeso
AU  - Palomera, Luis
AU  - García-Sanz, Ramón
AU  - Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
PY  - 2020
DO  - 10.1016/j.bbmt.2020.02.003
UR  - http://hdl.handle.net/10668/15119
T2  - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
AB  - Clinical trials have shown that nivolumab has remarkable activity against relapsed/refractory classical Hodgkin lymphoma (cHL). However, the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as consolidation therapy in these...
LA  - en
KW  - Allogeneic transplantation
KW  - Hodgkin lymphoma
KW  - Nivolumab
KW  - Relapsed/refractory lymphoma
KW  - Disease-Free Survival
KW  - Graft vs Host Disease
KW  - Hematopoietic Stem Cell Transplantation
KW  - Hodgkin Disease
KW  - Humans
KW  - Neoplasm Recurrence, Local
KW  - Nivolumab
KW  - Retrospective Studies
KW  - Spain
TI  - Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain.
TY  - research article
VL  - 26
ER  -